Reviva Pharmaceuticals Holdings

$RVPH bottomed out in August of last year, at which time the company came out with positive trial results for their phase 2 study of RP5063 (brilaroxazine) for Acute Schizophrenia. Since then the stock has gained in value and has done a pretty good job of holding those gains.

Share This Article

 

About the Author

Reviva Pharmaceuticals Holdings

Joey Ramson